• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by agilon health inc.

    9/10/24 10:47:52 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care
    Get the next $AGL alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 AGILON HEALTH INC COMMON STOCK Cusip #00857U107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00857U107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 28,153,797 Item 6: 0 Item 7: 28,156,051 Item 8: 0 Item 9: 28,156,051 Item 11: 6.842% Item 12: HC Cusip #00857U107 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 28,156,051 Item 8: 0 Item 9: 28,156,051 Item 11: 6.842% Item 12: IN Item 1(a). Name of Issuer: AGILON HEALTH INC Item 1(b). Address of Issuer's Principal Executive Offices: 6210 E HWY 290, Suite 450 Austin, TX 78723 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 00857U107 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 28,156,051 (b) Percent of Class: 6.842% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 28,156,051 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of AGILON HEALTH INC. No one other person's interest in the COMMON STOCK of AGILON HEALTH INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. September 9, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on September 9, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of AGILON HEALTH INC at August 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $AGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGL

    DatePrice TargetRatingAnalyst
    4/25/2025$5.00Neutral → Buy
    Citigroup
    4/8/2025$8.50Mkt Perform → Outperform
    Bernstein
    1/10/2025$1.75 → $2.25Sell → Neutral
    Citigroup
    1/10/2025Hold
    Needham
    12/16/2024Neutral
    Macquarie
    12/11/2024$2.50Mkt Perform
    Bernstein
    11/11/2024Mkt Outperform → Mkt Perform
    JMP Securities
    11/8/2024Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $AGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Schwaneke Jeffrey A. bought $250,206 worth of shares (22,300 units at $11.22) and was granted 428,922 shares, increasing direct ownership by 61% to 1,130,552 units (SEC Form 4)

      4/A - agilon health, inc. (0001831097) (Issuer)

      4/3/25 7:40:25 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • CEO & President Sell Steven covered exercise/tax liability with 15,563 shares and bought 42,426 shares, increasing direct ownership by 8% to 355,310 units (SEC Form 4)

      4 - agilon health, inc. (0001831097) (Issuer)

      3/18/25 6:42:37 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Chief Markets Officer Shaker Benjamin bought 11,786 shares and covered exercise/tax liability with 4,143 shares, increasing direct ownership by 2% to 457,058 units (SEC Form 4)

      4 - agilon health, inc. (0001831097) (Issuer)

      3/18/25 6:41:48 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    SEC Filings

    See more

    $AGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $AGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $AGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • agilon health inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - agilon health, inc. (0001831097) (Filer)

      5/30/25 4:43:53 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.

      SCHEDULE 13G/A - agilon health, inc. (0001831097) (Subject)

      5/13/25 11:44:13 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.

      SCHEDULE 13G/A - agilon health, inc. (0001831097) (Subject)

      5/12/25 10:44:45 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Agilon Health upgraded by Citigroup with a new price target

      Citigroup upgraded Agilon Health from Neutral to Buy and set a new price target of $5.00

      4/25/25 8:23:09 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Agilon Health upgraded by Bernstein with a new price target

      Bernstein upgraded Agilon Health from Mkt Perform to Outperform and set a new price target of $8.50

      4/8/25 9:06:22 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Agilon Health upgraded by Citigroup with a new price target

      Citigroup upgraded Agilon Health from Sell to Neutral and set a new price target of $2.25 from $1.75 previously

      1/10/25 7:25:30 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by agilon health inc.

      SC 13G/A - agilon health, inc. (0001831097) (Subject)

      11/13/24 12:49:26 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by agilon health inc.

      SC 13G/A - agilon health, inc. (0001831097) (Subject)

      11/8/24 10:52:39 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by agilon health inc.

      SC 13G/A - agilon health, inc. (0001831097) (Subject)

      11/6/24 4:47:14 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health to Participate in Bernstein's 41st Annual Strategic Decisions Conference

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will participate in the Bernstein 41st Annual Strategic Decisions Conference including a fireside chat presentation on Wednesday, May 28 at 4:30 PM Eastern Time. Interested investors and other parties may listen to a simultaneous webcast of the presentation by visiting the "Events & Presentations" section of agilon health's investor relations website at https://investors.agilonhealth.com. Replays will be available for on-demand listening shortly after the completion of the presentation. About agilon health agilon health is the trusted partner empowering

      5/19/25 4:04:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health to Participate in BofA Securities 2025 Health Care Conference

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will participate in the BofA Securities 2025 Health Care Conference including a fireside chat presentation on Wednesday, May 14 at 1:00 PM Eastern Time. Interested investors and other parties may listen to a simultaneous webcast of the presentation by visiting the "Events & Presentations" section of agilon health's investor relations website at https://investors.agilonhealth.com. Replays will be available for on-demand listening shortly after the completion of the presentation. About agilon health agilon health is the trusted partner empowering physicia

      4/4/25 4:15:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health Sets Date to Report First Quarter 2025 Financial Results

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the first quarter 2025 after the market closes on Tuesday, May 6, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 095319. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the ca

      3/25/25 4:05:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    Leadership Updates

    Live Leadership Updates

    See more
    • agilon health Appoints Karthik Rao, M.D., as Chief Medical Officer

      Dr. Rao to Continue to Lead Clinical Strategy and Drive Physician Network Performance Alongside agilon's Chief Clinical Officer Kevin Spencer, M.D. agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that after a comprehensive search Karthik Rao, M.D., who has served as agilon's interim chief medical officer (CMO) since February 2024, has been appointed to the permanent CMO role, effective immediately. He previously served as senior medical director and vice president, network performance, at the company. Prior to joining agilon in 2022, Dr. Rao held several roles in value-based care, including nearly a d

      7/10/24 8:00:00 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health Names Jeff Schwaneke New Chief Financial Officer

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Jeff Schwaneke, an experienced finance, operational and managed care executive and director on agilon's board, will join the Company as chief financial officer and executive vice president effective July 1, 2024. He will be a member of agilon's Executive Leadership team reporting to chief executive officer (CEO), Steve Sell. Schwaneke succeeds Timothy Bensley, who announced his retirement from agilon in early 2024. Bensley has agreed to stay on through a transition period. Schwaneke was most recently executive vice president, Health Care Enterprises,

      6/5/24 8:00:00 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health, inc. investors: Please contact the Portnoy Law Firm to recover your losses; May 28, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises agilon health, inc. (NYSE:AGL) investors that a lawsuit was filed on behalf of investors that purchased agilon securities between April 15, 2021 and February 27, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to

      5/13/24 6:31:12 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    Financials

    Live finance-specific insights

    See more
    • agilon health Sets Date to Report First Quarter 2025 Financial Results

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the first quarter 2025 after the market closes on Tuesday, May 6, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 095319. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the ca

      3/25/25 4:05:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health Sets Date to Report Fourth Quarter and Full Year 2024 Financial Results

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health in our communities, announced that it will release its financial results for the fourth quarter and full year 2024 after the market closes on Tuesday February 25, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 599648. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A

      2/10/25 4:01:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health Reports Third Quarter 2024 Results

      Revenue increased 28% to $1.45 billion, Medicare Advantage membership increased 37% to 525,000, and total members on the agilon platform grew 39% to 657,000 Third quarter results were affected by lower-than-expected 2024 risk adjustment, negative prior year development mainly from risk adjustment and Part D, and higher current year medical expenses Adjusted full year guidance reflects Q3 results and updated Q4 cost trends agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the third quarter ended September 30, 2024. "Our full-risk model enables primary care physicians to deliver high-quality c

      11/7/24 4:00:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Schwaneke Jeffrey A. covered exercise/tax liability with 9,331 shares, decreasing direct ownership by 0.83% to 1,121,221 units (SEC Form 4)

      4 - agilon health, inc. (0001831097) (Issuer)

      5/30/25 8:11:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Director Mckenzie Diana was granted 78,724 shares, increasing direct ownership by 134% to 137,543 units (SEC Form 4)

      4 - agilon health, inc. (0001831097) (Issuer)

      5/30/25 7:39:34 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Director Wulf John William was granted 78,724 shares, increasing direct ownership by 38% to 284,857 units (SEC Form 4)

      4 - agilon health, inc. (0001831097) (Issuer)

      5/30/25 6:32:44 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care